Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
USV pegfilgrastim versus Neulasta in breast cancer patients receiving myelosuppressive chemotherapy
2015-000266-64Phase 3Completed
- Sponsor
- USV
- Start
- May 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of pegfilgrastim in neutropenia and febrile neutropenia (FN) (2 arms), sponsored by USV. Primary endpoint: Mean duration of severe neutropenia during cycle 1. Started May 2015; status: completed.
02
Drugs
pegfilgrastim
03
Conditions
neutropeniafebrile neutropenia (FN)
Beyond the preview
Go deeper on 2015-000266-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000266-64.